Last reviewed · How we verify
EGP-437 with EyeGate® II System
EGP-437 is a corticosteroid delivered directly to the eye via the EyeGate® II iontophoresis system to reduce ocular inflammation.
EGP-437 is a corticosteroid delivered directly to the eye via the EyeGate® II iontophoresis system to reduce ocular inflammation. Used for Macular edema associated with retinal vein occlusion, Uveitis and other posterior segment inflammatory conditions.
At a glance
| Generic name | EGP-437 with EyeGate® II System |
|---|---|
| Also known as | Dexamethasone phosphate ophthalmic solution |
| Sponsor | Eyegate Pharmaceuticals, Inc. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
EGP-437 is a dexamethasone analog formulated for transscleral iontophoretic delivery, which uses electrical current to enhance drug penetration through the sclera into the posterior segment of the eye. This targeted delivery approach aims to achieve therapeutic concentrations in the back of the eye while minimizing systemic exposure and anterior segment side effects associated with topical or systemic corticosteroids.
Approved indications
- Macular edema associated with retinal vein occlusion
- Uveitis and other posterior segment inflammatory conditions
Common side effects
- Ocular discomfort or irritation at iontophoresis site
- Elevated intraocular pressure
- Cataract progression
Key clinical trials
- Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis (PHASE2)
- Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EGP-437 with EyeGate® II System CI brief — competitive landscape report
- EGP-437 with EyeGate® II System updates RSS · CI watch RSS
- Eyegate Pharmaceuticals, Inc. portfolio CI